Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sarilumab for Moderate COVID-19
NCT04359901Phase 2Completed
- Start
- Apr 2020
- Primary completion
- Aug 2021
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in coronavirus disease 2019 (COVID-19) comparing Standard of care plus subcutaneous sarilumab with Standard of care (2 arms). Primary endpoint: Number of Participants With Intubation or Death at 14 days. Started Apr 2020; status: completed.
02
Drugs
sarilumab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04359901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04359901.